NCT-502
Based on 6 publication(s) in Google Scholar
NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.59%
- CAS No.: 1542213-00-2
- Formule: C18H20F3N5S
- Masse moléculaire:395.45
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NCT-502
More
Activité biologique
IC50: 3.7 μM (PHGDH)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
15.8 μM
Compound: 53
|
Cytotoxicity against human HepG2 cells assessed as cellular ATP content after 48 hrs by CellTiter-Glo assay
Cytotoxicity against human HepG2 cells assessed as cellular ATP content after 48 hrs by CellTiter-Glo assay
|
[PMID: 24450337] |
| MDA-MB-468 | EC50 |
15.2 μM
Compound: 27; NCT-502
|
Cytotoxicity against human MDA-MB-468 cells
Cytotoxicity against human MDA-MB-468 cells
|
[PMID: 29555419] |
NCT-502 is cytotoxic to MDA-MB-468, with an EC50 of 15.2 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1542213-00-2
-
Appearance Solid
-
Masse moléculaire 395.45
-
Formule C18H20F3N5S
-
Color Light yellow to yellow
-
SMILES
S=C(NC1=NC(C)=CC(C)=C1)N2CCN(CC2)C3=NC=C(C=C3)C(F)(F)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Multiomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn's disease. [Abstract]2021 Aug 10;54(8):1728-1744.e7. PMID: 34343498 -
Nat Commun
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. [Abstract]2020 Jul 3;11(1):3288. PMID: 32620753 -
Nat Chem Biol
2025 Jun 2. PMID: 40456963 -
Int J Biol Sci
PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. [Abstract]2022 Aug 29;18(14):5459-5474. PMID: 36147463 -
-
Solvant et solubilité
DMSO : 130 mg/mL (328.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (5.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5288 mL | 12.6438 mL | 25.2876 mL | 63.2191 mL |
| 5 mM | 0.5058 mL | 2.5288 mL | 5.0575 mL | 12.6438 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5288 mL | 6.3219 mL | |
| 15 mM | 0.1686 mL | 0.8429 mL | 1.6858 mL | 4.2146 mL | |
| 20 mM | 0.1264 mL | 0.6322 mL | 1.2644 mL | 3.1610 mL | |
| 25 mM | 0.1012 mL | 0.5058 mL | 1.0115 mL | 2.5288 mL | |
| 30 mM | 0.0843 mL | 0.4215 mL | 0.8429 mL | 2.1073 mL | |
| 40 mM | 0.0632 mL | 0.3161 mL | 0.6322 mL | 1.5805 mL | |
| 50 mM | 0.0506 mL | 0.2529 mL | 0.5058 mL | 1.2644 mL | |
| 60 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 1.0537 mL | |
| 80 mM | 0.0316 mL | 0.1580 mL | 0.3161 mL | 0.7902 mL | |
| 100 mM | 0.0253 mL | 0.1264 mL | 0.2529 mL | 0.6322 mL |
Powered by Bioz